- NCIt
- C162993
Loading cancer entity…
Loading cancer entity…
Clinical trials
187 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (32)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04837547 | PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy(PEACH) | active not recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04870944 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | recruiting | Phase 1 / Phase 2 | 63 | Children's Oncology GroupNETWORK | 2 | Sep 11, 2026 | clinicaltrials |
| NCT06639607 | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma(PRiME II) | suspended | Phase 1 / Phase 2 | 68 | Washington University School of MedicineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT06946680 | IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)(Peds IMPACT) | not yet recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03911388 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04991870 | Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM | recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03657576 | Trial of C134 in Patients With Recurrent GBM(C134-HSV-1) | completed | Phase 1 | 19 | University of Alabama at BirminghamOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | recruiting | Phase 1 / Phase 2 | 265 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06860594 | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07180927 | DLL3 CAR-T Therapy Targeting Brain Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT07796061 | Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)(LIFT) | not yet recruiting | Phase 1 | 45 | Children's National Research InstituteOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT07501156 | H3K27M-specific Immune Effector Cells Targeting DMG/DIPG | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | terminated | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT07767110 | Targeted LSAM-Cisplatin Infusion in Gliomas, Evaluation of Response(TIGER-1) | not yet recruiting | Phase 1 / Phase 2 | 20 | NanOlogy, LLCINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT06632236 | 5G-EMERALD: Amivantamab in Malignant Brain Tumours(5G-EMERALD) | active not recruiting | Phase 1 | 12 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06894979 | Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 54 | Children's Oncology GroupNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03389802 | Phase I Study of APX005M in Pediatric Central Nervous System Tumors | completed | Phase 1 | 32 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Aug 13, 2026 | clinicaltrials |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | active not recruiting | Phase 1 / Phase 2 | 10 | Julie KrystalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04099797 | C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) | recruiting | Phase 1 | 56 | Baylor College of MedicineOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06624371 | Atovaquone Combined With Radiation in Children With Malignant Brain Tumors(AflacBT2303) | recruiting | Phase 1 | 18 | Emory UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT03598244 | Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | active not recruiting | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 2 | Jul 30, 2026 | clinicaltrials |
| NCT07464925 | A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma | recruiting | Phase 1 | 30 | Tetragon Biosciences LtdINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT02359565 | Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma | active not recruiting | Phase 1 | 71 | National Cancer Institute (NCI)NIH | 2 | Jul 20, 2026 | clinicaltrials |
| NCT05278208 | Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors | recruiting | Phase 1 / Phase 2 | 65 | Nationwide Children's HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | terminated | Phase 1 | 1 | Chimeric TherapeuticsINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06914479 | Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors | recruiting | Phase 1 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04911621 | Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma(ADDICT-pedGLIO) | completed | Phase 1 / Phase 2 | 10 | University Hospital, AntwerpOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients(ADDIT-GLIO) | active not recruiting | Phase 1 / Phase 2 | 20 | University Hospital, AntwerpOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04978727 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 35 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT04222309 | Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) | suspended | Phase 1 | 10 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04968366 | Safety & Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery | completed | Phase 1 | 11 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | active not recruiting | Phase 1 | 64 | Nationwide Children's HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04943848 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | recruiting | Phase 1 | 36 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT01165333 | Cilengitide in Combination With Irradiation in Children With Diffuse Intrinsic Pontine Glioma(CILENT) | completed | Phase 1 | 32 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT06342908 | A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma | active not recruiting | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05762419 | FUS Etoposide for DMG | recruiting | Phase 1 | 10 | Columbia UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06815432 | GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06193174 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | terminated | Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06630260 | 5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours(5G-RUBY) | recruiting | Phase 1 / Phase 2 | 182 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07331064 | Gallium Maltolate for the Treatment of Pediatric Patients With Relapsed or Refractory Pediatric High-Grade Glioma and Atypical Teratoid Rhabdoid Tumor(GABRIEL) | not yet recruiting | Phase 1 | 15 | Sarah RumlerOTHER | 0 | Jan 9, 2026 | clinicaltrials |
| NCT04295759 | INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | completed | Phase 1 | 13 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05956821 | Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | recruiting | Phase 1 / Phase 2 | 20 | University of MiamiOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT05768880 | Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors | active not recruiting | Phase 1 | 72 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)(BRAVO) | terminated | Phase 1 | 11 | University of FloridaOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT07179328 | Focused Ultrasound Blood-Brain Barrier Disruption for the Treatment of High-Grade Glioma in Patients Undergoing Standard Chemotherapy | recruiting | Phase 1 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 17, 2025 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials